Donald Trump’s announcement that he plans to slap 25% tariffs on all car imports to the United States has given most ...

In part due to inflation, the Fed opted last week to maintain current interest rates, though it expects two rounds of cuts ...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to ...

RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced the release of its 2024 Sustainability Report covering the calendar year 2024.

Bullish on Zscaler, Inc. as AI-powered products drive growth, aiming for 22.5% upside. Click here to find out why ZS stock is ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

TROY, Mich., March 28, 2025 (GLOBE NEWSWIRE) -- Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the fourth quarter and year ended December 31, 2024.

Another wipeout is slamming Wall Street Friday as worries build about a potentially toxic mix of worsening inflation and a ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...